A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naive Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pexastimogene devacirepvec (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms FLASH
- Sponsors Jennerex
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jan 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.